{
    "nct_id": "NCT04839991",
    "official_title": "A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific HumabodyÂ® T-cell Enhancer, in Patients With PSMA+ Advanced and/or Metastatic Solid Tumours",
    "inclusion_criteria": "1. Capable of understanding the written informed consent\n2. Aged at least 18 years\n3. Not amenable to standard of care\n4. ECOG PS <=2\n5. Has documented histologically confirmed diagnosis of PSMA+ advanced or metastatic solid tumours\n6. Has radiologically measurable disease per RECIST v1.1 or elevated serum PSA for castration resistant prostate cancer patients with only bone metastasis\n7. Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Subjects with autoimmune disease or regular immunosuppressants\n2. Has discontinued from anti-CTLA 4, anti-PD1 or anti-PD(L)1 antibody because of intolerable toxicity\n3. Has brain metastasis including leptomeningeal metastasis or primary brain tumour\n4. Has current or history of CNS disease\n5. Has known active infection\n6. Part 2B only - has prior treatment with anti PD(L)1 or anti CTLA4",
    "miscellaneous_criteria": ""
}